Paladin Labs Inc. and Bioniche Life Sciences Inc. Sign Debt Refinancing and Urocidin(TM) Licensing Deals

Corporate Breaking News

Home : Paladin Labs Inc. and Bioniche Life Sciences Inc. Sign Debt Refinancing and Urocidin(TM) Licensing Deals

Jun 06 2013	Paladin Labs Inc. and Bioniche Life Sciences Inc. Sign Debt Refinancing and Urocidin(TM) Licensing Deals
MONTREAL, QUEBEC--(Marketwired - June 5, 2013) - Bioniche Life Sciences Inc. (TSX:BNC)(ASX:BNC) ("Bioniche") and Paladin Labs Inc.(TSX:PLB) ("Paladin") today announced a comprehensive strategic collaboration to refinance and increase Bioniche's debt, provide new equity, and enter into the first licensing deal for Bioniche's Phase III bladder cancer product - UrocidinT.


Source:http://www.marketwire.com/mw/release.do?id=1798774&sourceType=3

Related News
» Laboratoires Paladin Inc. et Bioniche Life Sciences Inc. concluent le refinancement de la dette et signent une entente de licence pour Urocidin(MC) » Woman Pulled From Philadelphia Building Collapse